“Our large-scale, international, real-world analysis supports the absence of a clinical benefit of chloroquine and hydroxychloroquine and points to potential harm in hospitalised patients with COVID-19,” the study reads.
Hydroxychloroquine can prevent lupus flares and increase long-term survival of patients with the disease. Without it, however, lupus patients stand to endure more pain and suffering.
Dr. Rick Bright alleges he was reassigned to a lesser role because he resisted political pressure to allow widespread use of hydroxychloroquine, a malaria drug favored by President Trump.
In a nationwide study of 368 patients in U.S. veterans hospitals, 28% who received hydroxychloroquine and usual care died, versus 11% of those getting only routine care.